India's First Drug EMR Could Set Off Litigation Wave, Industry Warns

Law360, New York (November 13, 2003, 12:00 AM EST) -- The grant of India's first exclusive marketing right (EMR) to Swiss drugmaker Novartis for its leukemia medicine Gilvec (imatinib mesylate) could set off a wave of patent litigation, the Economic Times of India reported.

Novartis' EMR grant, issued by the Controller General of Patents and Trademarks of India, blocks the duplication and sale of the drug by any other company for five years.

"We are in an uncharted territory and we are evaluating all our options carefully. We hope that the Indian government will ensure the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.